Arena Pharmaceuticals Inc $4.77

up +0.06


30/7/2014 04:00 PM  |  NASDAQ : ARNA  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get ARNA Trend Analysis - it has underperformed the S&P 500 by 48%

Partner Headlines

  1. Benzinga's Top #PreMarket Losers

    Benzinga
  2. Markets Marginally Lower Ahead Of Earnings Season

    Benzinga
  3. Arena Pharmaceutical Shares Dive On News CEO Sold 40% Of His Shares

    Benzinga
  4. Benzinga's Top #PreMarket Losers

    Benzinga
  5. Events Scheduled for Week of Jun. 16th to Jun. 20th

    Benzinga
  6. FDA delays Orexigen drug

    IBD
  7. Is Arena Pharmaceuticals A Biotech Stock To Watch?

    Benzinga
  8. Orexigen Obesity Drug Decision Delayed By FDA

    IBD
  9. Orexigen Shares Plummet Following FDA Decision; Competition Gets A Bump

    Benzinga
  10. Arena Pharma Posts Q1 Loss Of $0.12/Share, Misses By ~$0.02/Share

    Benzinga
  11. Earnings Scheduled For May 12, 2014

    Benzinga
  12. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE Moving ...

    Benzinga
  13. Benzinga's Top #PreMarket Losers

    Benzinga
  14. Earnings Scheduled For February 27, 2014

    Benzinga
  15. Bad Earnings Weigh In On Diet Stocks

    Benzinga
  16. Top Trending Tickers On StockTwits For February 14

    Benzinga
  17. #PreMarket Primer: Friday, February 14: A Turnaround

    Benzinga
  18. Arena Pharmaceuticals Announces Filing for Marketing Authorization of BELVIQ® ...

    Benzinga
  19. Celgene To Release Earnings At J.P. Morgan Event Mon.

    IBD
  20. The Top Five Drug Launches Of 2013

    IBD
  21. (ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance on Financial ...

    GuruFocus
  22. Benzinga's Top #PreMarket Gainers

    Benzinga
  23. Market Wrap For November 11: Relative Quiet as Traders and Investors Observe ...

    Benzinga
  24. Market Wrap For November 8: Markets Erase Thursday's Losses; Dow Companies ...

    Benzinga
  25. Arena Pharmaceuticals, Eisai Expand Marketing and Supply Agreement for ...

    Benzinga
  26. Nasdaq Leads Stocks Lower; Twitter IPO Opens To 80% Gain

    IBD
  27. How Arena’s “$3 Billion” Belviq Withered

    YCharts
  28. Benzinga's Top #PreMarket Losers

    Benzinga
  29. Market Wrap For Tuesday, October 15: Earnings Reports And White House Progress ...

    Benzinga
  30. Mid-Afternoon Market Update: Tumi Holdings Rises Amid Market Decline

    Benzinga
  31. Mid-Morning Market Update: Markets Slip; Citigroup Profit Misses Estimates

    Benzinga
  32. UPDATE: Arena Says Eisai Will Double BELVIQ Sales Force to 400 Reps

    Benzinga
  33. Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and Raises PT

    Benzinga
  34. Obesity Drug Stocks Jump As Cowen Gets Bullish

    IBD
  35. Benzinga's Top Pre-Market Losers

    Benzinga
  36. Market Wrap For September 30: Debt Ceiling And Government Shutdown Loom

    Benzinga
  37. Mid-Afternoon Market Update: Mellanox Rallies As Market Remains in the ...

    Benzinga
  38. Mid-Day Market Update: Dow Falls Over 100 Points; Active Network Shares ...

    Benzinga
  39. Mid-Morning Market Update: Markets Open Lower; Cal-Maine Q1 Net Profit ...

    Benzinga
  40. UPDATE: Credit Suisse Lowers PT on Arena Pharmaceuticals Following Management ...

    Benzinga
  41. Arena Pharma Offers Update on Eisai Launch of BELVIQ, Says Placing Ads ...

    Benzinga
  42. Stocks Hitting 52-Week Lows

    Benzinga
  43. BMO Considers Recent Sales Data on Arena's Belviq, Maintains Market Perform ...

    Benzinga
  44. CEO Shift Aside, Whose Weight-Loss Pill’s Ahead

    YCharts
  45. Stocks Hitting 52-Week Lows

    Benzinga
  46. Stocks Hitting 52-Week Lows

    Benzinga
  47. Arena Pharma Reports Closing of Phase 1b Clinical Trial for APD811

    Benzinga
  48. Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, VRTX)

    Benzinga
  49. It's Hard to Sell a Pill That Nobody's Heard Of

    YCharts
  50. Weekly Preview: Earnings Season Continues, Fed In Focus, Economic Maelstrom ...

    Benzinga
Trading Center